A number of popular ASX 200 shares have been making waves recently with some very strong returns.
But after such strong gains, is it now too late to buy these shares? Let's have a look and see if analysts believe they can go even higher from here. They are as follows:
Image source: Getty Images
Nextdc Ltd (ASX: NXT)
The NextDC share price is up 32% in under a month. This has been driven by a combination of a rebound in the tech sector and the release of a trading update from the data centre operator. The latter revealed a significant 30% or 52MW jump in contracted utilisation to 228MW since 31 December.
The ASX 200 share's CEO, Craig Scroggie, said: "We are very pleased to have recorded the largest increase in contracted utilisation in the Company's history. The rise of artificial intelligence and high-performance computing is reshaping the data centre industry at speed. Hyperscale customers are scaling AI-native infrastructure at unprecedented levels."
The good news is that Goldman Sachs believes there's still plenty of potential gains ahead. It has a buy rating and $16.50 price target on its shares. This suggests that upside of almost 19% is possible from current levels.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is up 33% in just under a month. As with NextDC, this has been driven by both a rebounding tech sector and the release of positive news from health imaging technology company. The latter relates to the announcement of a $20 million, five-year contract with the University of Iowa Health Care. It is Iowa's comprehensive academic health system.
Goldman Sachs also doesn't believe it is too late to buy this ASX 200 share. It has a buy rating and $309.00 price target on Pro Medicus' shares. This implies potential upside of 13.5% for investors over the next 12 months.
WiseTech Global Ltd (ASX: WTC)
The WiseTech Global share price has risen 30% since 22 April thanks to a strong rebound in the tech sector after the US and China signed a trade deal. This is good news for the logistics solutions platform provider as a trade war could've reduced demand for its software.
Morgan Stanley believes more strong returns are on the way. Last week, its analysts put an overweight rating and $140.00 price target on its shares. This suggests that upside of 36% is possible for investors.
